Cytosorbents (NASDAQ:CTSO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Saturday. The brokerage issued a hold rating on the medical research company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a report on Monday, November 11th.

Cytosorbents Trading Down 4.2 %

NASDAQ CTSO opened at $0.90 on Friday. The company’s fifty day moving average price is $0.93 and its two-hundred day moving average price is $1.02. The company has a market capitalization of $49.21 million, a price-to-earnings ratio of -2.50 and a beta of 0.57. Cytosorbents has a 12 month low of $0.70 and a 12 month high of $1.59. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. CM Management LLC grew its position in shares of Cytosorbents by 3.0% during the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after acquiring an additional 25,000 shares during the last quarter. Sargent Investment Group LLC boosted its stake in Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after purchasing an additional 67,181 shares during the period. Atomi Financial Group Inc. bought a new position in Cytosorbents in the 3rd quarter worth about $51,000. Finally, Geode Capital Management LLC increased its stake in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the period. 32.87% of the stock is currently owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.